Pacira BioSciences Inc (NASDAQ: PCRX) kicked off on Friday, up 5.93% from the previous trading day, before settling in for the closing price of $23.77. Over the past 52 weeks, PCRX has traded in a range of $11.16-$27.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -51.99% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -9.27%. With a float of $42.94 million, this company’s outstanding shares have now reached $44.90 million.
In an organization with 790 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 78.19%, operating margin of -14.78%, and the pretax margin is -15.1%.
Pacira BioSciences Inc (PCRX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Pacira BioSciences Inc is 4.43%, while institutional ownership is 116.57%. The most recent insider transaction that took place on Aug 07 ’25, was worth 116,279. Before that another transaction happened on Jun 04 ’25, when Company’s Senior Vice President, Finance sold 5,578 for $26.21, making the entire transaction worth $146,208. This insider now owns 59,564 shares in total.
Pacira BioSciences Inc (PCRX) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported 0.79 earnings per share (EPS), higher than consensus estimate (set at 0.7) by 0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.85 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.27% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.61% during the next five years compared to -51.99% drop over the previous five years of trading.
Pacira BioSciences Inc (NASDAQ: PCRX) Trading Performance Indicators
Take a look at Pacira BioSciences Inc’s (PCRX) current performance indicators. Last quarter, stock had a quick ratio of 1.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.60. Likewise, its price to free cash flow for the trailing twelve months is 9.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.79, a number that is poised to hit 0.66 in the next quarter and is forecasted to reach 3.40 in one year’s time.
Technical Analysis of Pacira BioSciences Inc (PCRX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.19 million. That was better than the volume of 0.81 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 78.58%.
During the past 100 days, Pacira BioSciences Inc’s (PCRX) raw stochastic average was set at 63.77%, which indicates a significant decrease from 98.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.14 in the past 14 days, which was higher than the 1.05 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.68, while its 200-day Moving Average is $22.66. However, in the short run, Pacira BioSciences Inc’s stock first resistance to watch stands at $25.77. Second resistance stands at $26.37. The third major resistance level sits at $27.50. If the price goes on to break the first support level at $24.04, it is likely to go to the next support level at $22.91. Assuming the price breaks the second support level, the third support level stands at $22.31.
Pacira BioSciences Inc (NASDAQ: PCRX) Key Stats
The company with the Market Capitalisation of 1.13 billion has total of 44,933K Shares Outstanding. Its annual sales at the moment are 700,970 K in contrast with the sum of -99,560 K annual income. Company’s last quarter sales were recorded 168,920 K and last quarter income was 4,810 K.
